GlassScriptPhysician profile
Brian G Kerr
NPI 1376587717
$3,509.31
in general payments reported to CMS, 2019-2025
37 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $337 · 2021: $822 · 2022: $358 · 2023: $910 · 2024: $516 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $871.98 | 2020-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $400.64 | 2020-2025 | |
| Inspire Medical Systems, INC. | $244.16 | 2023-2024 | Inspire |
| Phathom Pharmaceuticals, INC. | $242.72 | 2024 | Voquezna |
| Optinose US, INC. | $139.90 | 2019-2024 | |
| Abbott Laboratories | $139.48 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $137.45 | 2019-2024 | Evenity, Prolia |
| Medtronic, INC. | $136.11 | 2021 | |
| Access Pro Medical, LLC | $133.28 | 2023 | Matriderm |
| Acclarent, INC | $120.93 | 2019 | |
| Xeris Pharmaceuticals, INC. | $120.68 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $85.56 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $75.23 | 2022-2023 | Belsomra, Steglatro, Steglujan |
| Insulet Corporation | $71.46 | 2020-2023 | Omnipod |
| Dexcom, INC. | $63.72 | 2023-2025 | Dexcom G6 Transmitter |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $58.70 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Stryker Corporation | $46.56 | 2019-2025 | Audion Et Dilation System |
| Novo Nordisk INC | $45.47 | 2023 | Rybelsus |
| Pharming Healthcare, INC. | $35.53 | 2023-2024 | Ruconest |
| C2dx, INC | $32.94 | 2023 | |
| Tandem Diabetes Care, INC. | $27.00 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $26.92 | 2024 | Korlym |
| Shire North American Group INC | $25.70 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.20 | 2023 | |
| Beta Bionics, INC. | $22.43 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Horizon Therapeutics Plc | $19.82 | 2020 | |
| Halozyme INC | $18.40 | 2023 | |
| Eusa Pharma (US) LLC | $17.37 | 2022 | |
| Recordati_rare_diseases_inc. | $17.37 | 2022 | |
| Amryt Pharma Holdings LTD | $17.25 | 2023 | Mycapssa |
| Ipsen Biopharmaceuticals, INC | $16.96 | 2021 | |
| Glaxosmithkline, LLC. | $16.92 | 2025 | Nucala |
| Intersect Ent, INC. | $16.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.83 | 2022 | |
| Olympus America INC. | $13.14 | 2024 | Gyrus Acmi, INC, Rhino-Laryngo Videoscope |
| Abbvie INC. | $12.63 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,762,336.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kerr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.